Early and delayed clinical cardiotoxicity of doxorubicin
Why the study?
Does doxorubicin treatment cause early and delayed congestive heart failure in breast cancer patients?
Population
n=534 evaluable patients with breast cancer (Stage II or III disease, or isolated recurrences).
Design
Cohort
Follow-up
median 68 months
Authors
Discussion
Loading...
Member takes
Implication
Doxorubicin-associated CHF risk rises dose-dependently with early onset; supports monitoring but leaves open causality and generalizability.
Structured PICO
Does doxorubicin treatment cause early and delayed congestive heart failure in breast cancer patients?
P
Population
n=534 evaluable patients with breast cancer (Stage II or III disease, or isolated recurrences).
I
Intervention
Combination of 5-fluorouracil, doxorubicin, and cyclophosphamide. Total planned dose of doxorubicin was 300 mg/m2 in patients with Stage II or III disease, and 450 mg/m2 in patients with isolated recurrences.
O
Outcome
Congestive heart failure associated with doxorubicinsafety
Doxorubicin-induced congestive heart failure is dose-dependent and typically occurs early, with no delayed cases observed after 3 years of follow-up.
Cite This Study
Buzdar et al. (1985) studied this question.